It is with great pleasure that the EspeRare foundation welcomes a new member to its board, Mr. Denis Mortier. Denis brings core business and financial strategy acumen to the board’s expertise. His addition will support the current scale-up of EspeRare’s operations and R&D activities in order to reach even more children suffering with rare diseases.
“Denis has been recently closely involved with EspeRare and has already had a considerable impact on shaping the foundation’s growth strategy. Denis has an outstanding track record in building financial strategies, and we are honoured and delighted to include him on our board. EspeRare will leverage on his wealth of experience to further its growth, and ultimately to enable EspeRare to better deliver on its mission” commented Caroline Kant, executive director.
Denis has held senior and executive positions within several private finance sector companies. Amongst others, Denis has served as a partner of Coller Capital Ltd (UK). He was also appointed on the executive committees of both the Atomic Energy Commission (CEA, France) and of Credit National (France). He was the founding CEO of CEA Industrie and of Financière Saint Dominique. He served as an executive officer for the World Bank Group, as Chairman for the European Private Equity and Venture Capital Association (EVCA), as well as vice chairman of NASDAQ Europe. He also served on advisory boards and investment committees for multiple venture capital funds. Denis completed his undergraduate studies at the “Ecole des Hautes Etudes Commerciales” (HEC) in Paris and also holds an MBA from Stanford Business School.
As a private non-for-profit organisation, we strive to uncover the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, thus giving better chances to existing drugs to reach these underserved patients.